Latest Lead News

Cynata Therapeutics has finalised patient enrolment in its pivotal Phase 2 trial of CYP-001 for acute graft versus host disease, setting the stage for critical data due mid-2026.

Fortifai Limited introduces Nol8, a breakthrough platform that processes data in real time with millisecond latency, promising to transform industries reliant on massive data flows.

Fortifai Limited has acquired an exclusive license to Nol8, a breakthrough real-time data processing technology developed by the Technion. This acquisition positions Fortifai to revolutionize data handling across gaming, AI, finance, and cybersecurity sectors.

Godolphin Resources has significantly upgraded its Lewis Ponds deposit, increasing total tonnage by 78% and gold content by 34%, setting the stage for an upcoming scoping study.

Future Metals NL has completed strategic planning that enhances its flagship Panton PGM Project’s value, driven by a 35% rise in platinum group metal prices and expanded exploration programs. The company is also advancing infrastructure options and strengthening its management team to accelerate development.

Amaero Ltd has secured a significant endorsement from the U.S. Department of the Navy for its Powder Metallurgy Hot Isostatic Pressing (PM-HIP) technology, positioning it as a key solution to long lead times in defense manufacturing.

Energy Resources of Australia has been granted a new rehabilitation authority to extend its environmental restoration work at the Ranger Project Area beyond January 2026.

Ovanti’s US payments brand Flote has partnered with cloud-native platform Gr4vy to launch scalable, responsible buy now pay later solutions in the US market starting 2026.

Minerals 260 Limited has reported exceptional high-grade gold intercepts at its 4.5Moz Bullabulling Gold Project in Western Australia, highlighting significant resource growth potential beyond the recent estimate. The latest drilling results reinforce the project's robust mineralisation continuity and set the stage for an updated resource estimate in 2026.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Proteomics International's PromarkerD blood test shows clinically meaningful accuracy in predicting diabetic kidney disease among Aboriginal Australians, matching performance in non-Indigenous populations. This advancement offers a promising tool for early intervention in a high-risk group.

Aurora Labs has signed a landmark MOU with European defence giant MBDA to explore integrating its 3D-printed turbojet engines into advanced missile systems, marking a significant step into international defence markets.